How does pasireotide differ from first-generation somatostatin analogs?

Pasireotide has a broader binding profile, with significantly higher affinity for SSTR1, SSTR3, and SSTR5 compared to first-generation analogs like octreotide, which primarily target SSTR2.

Why is hyperglycemia a common concern with pasireotide?

Pasireotide inhibits the secretion of insulin and incretins, which can lead to elevated blood glucose levels and, in some cases, the development of diabetes.

What conditions is pasireotide studied for?

It is primarily studied and used in the management of acromegaly and Cushing's disease, particularly in cases where other medical therapies have been insufficient.

Does pasireotide require dosage adjustments for renal impairment?

Based on clinical pharmacology studies, dosage adjustment is generally not required for patients with renal impairment.

What are the primary receptor targets of pasireotide?

Pasireotide targets somatostatin receptor subtypes 1, 2, 3, and 5.

Back to Library

Last reviewed: October 2026

Pasireotide

Endocrine / Hormonal|Synthetic cyclic hexapeptide somatostatin analog

Also known as: SOM230

Evidence Snapshot

PubMed-Indexed Literature

772 exact-name search results

References Reviewed

10 indexed references used for this page

Molecular Record

PubChem CID 9941444

Evidence Scope

The evidence base for pasireotide consists of extensive in vitro receptor binding studies, phase III clinical trials in neuroendocrine disorders, and ongoing observational research regarding long-term efficacy and safety.

Key Takeaways

Pasireotide exhibits a broader binding affinity profile for SSTR subtypes compared to first-generation somatostatin analogs like octreotide.
It is primarily utilized in clinical research and therapeutic contexts for conditions involving hormone hypersecretion, such as acromegaly and Cushing's disease.
The drug's multi-receptor activity, particularly at SSTR5, is a key factor in its efficacy for tumors that may be resistant to first-generation analogs.
Clinical use is frequently associated with metabolic side effects, including hyperglycemia, due to the inhibition of insulin and incretin secretion.
Evidence supports its role in biochemical control for patients with acromegaly who have not achieved sufficient response with other therapies.

Table of Contents

1.Overview

Pasireotide is a synthetic, long-acting cyclic peptide designed to mimic the inhibitory effects of endogenous somatostatin. Unlike first-generation somatostatin analogs (SRLs) that primarily target SSTR2, pasireotide was developed to provide a more comprehensive receptor coverage, which is hypothesized to improve therapeutic outcomes in hormone-secreting tumors.

2.Mechanism of Action

The pharmacological activity of pasireotide is mediated through its interaction with the G protein-coupled somatostatin receptors. By binding to SSTR1, 2, 3, and 5, it triggers intracellular signaling cascades that suppress the release of various hormones. In the context of pituitary adenomas, this mechanism is critical for reducing the hypersecretion of GH and ACTH, which are the drivers of acromegaly and Cushing's disease, respectively.

3.Why Researchers Study It

Research interest in pasireotide centers on its potential to overcome resistance to traditional SRLs. Because many somatotroph adenomas express a variety of SSTRs, the ability of pasireotide to engage SSTR5—which is often highly expressed in these tumors—remains a primary focus of clinical investigation. Additionally, researchers are studying the long-term anti-tumor effects and the management of its metabolic side-effect profile.

4.Pharmacology & Molecular Identity

Pasireotide is characterized by a high binding affinity for SSTR1, 3, and 5, and a comparable affinity for SSTR2 relative to other analogs. It has a half-life of approximately 12 hours. Pharmacologically, it is known to inhibit the secretion of insulin and glucagon, which frequently leads to alterations in glucose homeostasis. While its binding profile is well-documented in vitro, the clinical translation of these receptor interactions continues to be a subject of study in various neuroendocrine tumor models.

5.Human Research Evidence

Human evidence is primarily derived from phase III clinical trials evaluating its efficacy in acromegaly and Cushing's disease. Studies have demonstrated that pasireotide can achieve biochemical control in patients who are inadequately controlled by first-generation SRLs. Evidence also highlights its role in reducing ACTH levels in patients with Cushing's disease, though this is often accompanied by significant metabolic monitoring requirements.

6.Preclinical Research

Preclinical evidence, including in vitro competition binding assays and cell culture models, has consistently shown that pasireotide possesses a broader functional range than octreotide. These studies have been instrumental in mapping the expression of SSTR subtypes in various neuroendocrine tissues and predicting the drug's potential efficacy in suppressing hormone release in resistant tumor cell lines.

7.Safety & Research Limitations

The primary safety limitation associated with pasireotide is its impact on glucose metabolism. Because it inhibits insulin secretion, patients often experience hyperglycemia or the development of diabetes mellitus. Other observed effects include gastrointestinal disturbances and potential impacts on gallbladder function. These limitations necessitate careful clinical monitoring of blood glucose and other metabolic markers during administration.

8.Evidence Quality & Research Gaps

Current research gaps include the long-term durability of anti-tumor effects and the optimal management strategies for the metabolic side effects associated with chronic use. Further investigation is also required to determine if specific SSTR expression profiles can reliably predict patient response to therapy, as well as the potential for combination therapies to enhance efficacy while mitigating metabolic risks.

9.Frequently Asked Questions

10.References

1.Authors not listed. Pasireotide. . 2012.PMID: 31644171
2.Gadelha MR, Kasuki L. Refractory somatotroph adenomas. Pituitary. 2023 Jun. DOI: 10.1007/s11102-023-01324-5.PMID: 37316636
3.Authors not listed. Pasireotide. . 2006.PMID: 31145573
4.Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P. Acromegaly. Nature reviews. Disease primers. 2019 Mar 21. DOI: 10.1038/s41572-019-0071-6.PMID: 30899019
5.Valea A, Sandru F, Petca A, Dumitrascu MC, Carsote M. Aggressive prolactinoma (Review). Experimental and therapeutic medicine. 2022 Jan. DOI: 10.3892/etm.2021.10997.PMID: 34934445
6.Violetis O, Alexandraki KI. New Trends in Treating Cushing's Disease. TouchREVIEWS in endocrinology. 2024 Oct. DOI: 10.17925/EE.2024.20.2.3.PMID: 39526050
7.Araujo-Castro M, Lamas C, Nowak E, Newell-Price J, Reincke M. Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome. Endocrine reviews. 2026 May 13. DOI: 10.1210/endrev/bnaf042.PMID: 41489578
8.Castinetti F, Ioachimescu AG. Current treatment landscape of acromegaly. The Journal of clinical endocrinology and metabolism. 2026 Jun 4. DOI: 10.1210/clinem/dgag152.PMID: 41965092
9.Thanabalasingham G, Grossman AB. Acromegaly: Beyond surgery. Indian journal of endocrinology and metabolism. 2013 Jul. DOI: 10.4103/2230-8210.113721.PMID: 23961470
10.van der Groef R, Veldhuijzen van Zanten S, van Beekveld D, Mulugeta E, Refardt J. Long-term antitumour effects of pasireotide in acromegaly. European journal of endocrinology. 2025 Sep 30. DOI: 10.1093/ejendo/lvaf194.PMID: 40974037

Compound Command Center

Linked Research Evidence (0)

Published studies and registry summaries. Trial registration alone is not evidence of efficacy.

No linked research articles yet.